CGT Catapult has formed a consortium aimed at advancing technological development and reducing manufacturing costs for cell and gene therapies.
The Cell and Gene Therapy Catapult (CGT Catapult) has formed a consortium of more than 20 organizations aimed at advancing technology development and reducing the costs of manufacturing cell and gene therapy.
In a June 8, 2021 press release, CGT Catapult announced the formation of the consortium, which will evaluate several new or commonly used process analysis (PAT) technologies in other industries. Through collaboration and information sharing, the consortium will act as a catalyst to accelerate the development of the necessary knowledge and understanding at reduced cost and investment risk for each organization.
“The industry needs to take a giant leap forward in terms of analytical capacity and the dynamic use of information to control and improve processes, products and costs,” said Matthew Durdy, CEO of CGT Catapult, in the press release. hurry. “Bringing these leaders together in the field is a very important first step towards achieving this goal. “
“By sharing knowledge and data, consortium members will be able to reap potentially enormous benefits that could lead to more efficient processes in this vital area,” added Nicholas Medcalf, Deputy Director of the Challenge — Medicines Manufacturing for Innovate UK, in the press release. “The Cell and Gene Therapy Catapult, supported by Innovate UK, demonstrates its fantastic convening power by harnessing these key industry players for the greater good of business and innovation in the UK. “
Source: CGT Catapulte